Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 18
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/28/2008
 
First Published:
10/1/2000
1.
Phase III Randomized Study of Ondansetron in Patients With Advanced Cancer and Chronic Nausea and Emesis Not Due to Antineoplastic Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
Not specified
NCI
NCCTG-989201
NCI-P00-0168, NCT00006348
Last Modified:
4/20/2007
 
First Published:
5/1/2001
2.
Phase III Randomized Study of Ondansetron With or Without Dexamethasone as Prophylaxis for Radiation-Induced Emesis in Patients Receiving Upper Abdominal Radiotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
16 and over
Other
CAN-NCIC-SC19
NCT00016380, SC19
Last Modified:
12/4/2006
 
First Published:
7/1/2001
3.
Phase III Randomized Study of 3 Regimens For the Prevention of Delayed Nausea After Chemotherapy in Patients With Chemotherapy-Naive Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
NCI
URCC-U3901
NCI-P01-0180, NCT00020657
Last Modified:
3/1/1992
4.
Phase III Study of Ondansetron vs Droperidol for the Treatment of Immunotherapy-Induced Emesis (Summary Last Modified 03/92)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
NCI
NCI-92-C-0043
NCI-T91-0277N, T91-0277
Last Modified:
5/31/2007
 
First Published:
8/1/1999
5.
Phase II Randomized Study of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy Induced Nausea and Vomiting
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Closed
18 and over
Other
URCC-U3997
NCI-V99-1528, NCT00003817
Last Modified:
12/1/1995
6.
Phase II Study of CDDP/CBDCA with Ondansetron or Granisetron and G-CSF in Patients with Stage III/IV Epithelial Ovarian Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Closed
no age specified
Other
NBSG-9204
NCI-V92-0153
Last Modified:
11/8/2006
7.
Phase II Study of CDDP/CTX/DOX with G-CSF and Ondansetron in Patients with Metastatic or Recurrent Adenocarcinoma of the Endometrium
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Closed
18 and over
Other
NBSG-9206
NCI-V92-0158
Last Modified:
12/1/1993
8.
Phase II Study of Single-Dose Intravenous Ondansetron/Dexamethasone to Control Acute Vomiting Followed by Oral Dexamethasone/Prochlorperazine to Control Delayed Vomiting in Patients Receiving High-Dose Doxorubicin (Summary Last Modified 12/93)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Completed
18 and over
MSKCC-93098
NCI-V93-0318
9.
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Temporarily closed
18 to 85
Pharmaceutical / Industry
Rafa protocol THC002/NVP
NCT00285051
Last Modified:
11/8/2006
 
First Published:
7/1/2000
10.
Randomized Study of the Efficacy of Patient Information in Alleviating Nausea and Emesis in Cancer Patients Receiving Chemotherapy (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Educational/Counseling/Training
Closed
18 and over
NCI
URCC-3996
NCI-P00-0160, NCT00005994
Select All on One Page
1
2
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute